Advances in Therapeutic Strategies for Fibrodysplasia Ossificans Progressiva: From Symptom Management to Targeted Therapies
1, 1, 2
- 1Department of Pharmacology, MET’s Institute of D.Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, Maharashtra, INDIA.
- 2Department of Pharmacognosy, MET’s Institute of D.Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, Maharashtra, INDIA.
CORRESPONDENCE
Rutuja Sudam Binnar
Department of Pharmacology, MET’s Institute of D.Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, Maharashtra, INDIA.
Received: 25-12-2025; Revised: 11-02-2026; Accepted: 06-04-2026.
Volume 15, Issue 1 · pp. 37-44 · 2026 · DOI: 10.5530/ajbls.20260086
ABSTRACT
Muscles, tendons, and ligaments are part of the soft tissues that can develop progressive heterotopic ossification in Fibrodysplasia Ossificans Progressiva (FOP), a very rare genetic disorder that follows an autosomal dominant pattern. About one in every two million people worldwide are affected by this condition. Because FOP can resemble other disorders such as sarcoma, fibromatosis, and congenital skeletal abnormalities, early diagnosis is often challenging. Current management mainly focuses on symptomatic treatment, including the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 inhibitors for pain relief and short-term corticosteroids during acute flare-ups. The aim of this review is to summarize current understanding of the molecular basis of FOP, particularly the role of ACVR1 mutations, and to evaluate existing supportive treatments along with emerging targeted and gene-based therapeutic strategies that may help slow disease progression.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Binnar, R. S., Patil, R. N., & Shaikh, M. R. N. (2026). Advances in Therapeutic Strategies for Fibrodysplasia Ossificans Progressiva: From Symptom Management to Targeted Therapies. Asian Journal of Biological and Life Sciences, 15(1), 37-44. https://doi.org/10.5530/ajbls.20260086
Copyright and licence
© 2026 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0
